Table 1.
Patient demographics, baseline characteristics, treatment regimen, and outcome at the last follow-up.
| Patient characteristics | Number of patients (%) |
|---|---|
| Stage | |
| I/II | 7 (41.2) |
| III | 10 (58.8) |
| Histology | |
| Squamous cell carcinoma | 9 (52.9) |
| Adenocarcinoma | 8 (47.1) |
| Sex | |
| Female | 11 (64.7) |
| Male | 6 (35.3) |
| Smoking status | |
| Light | 4 (23.5) |
| Moderate | 6 (35.3) |
| Heavy | 6 (35.3) |
| Unknown | 1 (5.9) |
| Radiotherapy | |
| SBRT | 5 (29.4) |
| Conventional RT | 12 (70.6) |
| Systemic chemotherapy | 10 (58.8) |
| No systemic chemotherapy | 7 (41.2) |
| Adjuvant Durvalumab | 5 (29.4) |
| No adjuvant Durvalumab | 12 (70.6) |
| Recurrence | |
| Yes | 9 (52.9) |
| No | 8 (47.1) |
| Deceased by 10/26/2021 | 8 (47.1) |
| Alive on 10/26/2021 | 9 (52.9) |
SBRT, stereotactic body radiotherapy; ICI, RT, radiotherapy.